June 2009
Seraphim Capital Fund and Oxford Capital Partners invest further £1.2 million in Sirigen
Seraphim Capital and Oxford Capital Partners have invested a further £1.2 million into Sirigen - the company applying ground-breaking, Nobel Prize winning light amplification technology for use in the diagnostic and life science sectors. The round follows the £2 million previously invested in April 2008.
Mark Boggett, Investment Director at Seraphim Capital says “In spite of the impact of the adverse economic climate, Sirigen has made tremendous strides over the last 12 months, entering into commercial agreements with several global leading diagnostics companies. This is testimony to the strength of its game-changing technology which now stands at the forefront of the next generation of innovation within the diagnostics industry. We are delighted to continue to support the Company’s as it goes from strength to strength.”
Full press release can be viewed here
June 2009
Chris Day joins Sirigen as the new Financial Controller
Chris Day joined Sirigen in 2009. He has an extensive background in banking and finance and is a member of the Chartered Institute of Bankers. He brings with him a wide range of experience in all financial areas of commercial life and has worked for the past 11 years as Financial Controller for Fibercore Limited, a UK subsidiary of Cisco Systems Inc.
We are delighted to welcome him as a member of the Sirigen team.
May 2009
Sirigen inks commercial deals for Project Green
Sirigen is pleased to announce that it has signed commercial contracts with two major companies for “Project Green” - the early access program for development of a novel bright 532nm polymer-streptavidin conjugate to replace phycoerthyrin (PE). This novel chemical dye has relevance for a variety of key applications including the Luminex platform.
It is anticipated that the new conjugate label will be completed for the collaborative program members during Quarter 4 of this year.
April 2009
Sirigen launches customer demonstration seminars at its San Diego labs.
Sirigen is pleased to announce that we will be running frequent demonstration days at our San Diego facility to give interested parties firsthand experience of High Sensitivity Fluorescence.
If you would like to see with your own eyes how Sirigen’s technology can transform your applications please register your interest and book a date using the form on our customer support web page.
March 2009
Sirigen’s chemistry team expands with the appointment of Yongchao Liang.
Yongchao Liang joined Sirigen Inc in March of 2009. He received his PhD from the University of California Irvine and his MS from Chinese Academy of Sciences.
Dr. Liang brings a multitude of experience in organic synthesis, purification, electroluminescent polymers and has worked in both pre-clinical and clinical trial study in the cGMP manufacturing environment. With the benefit of experience in scientific entrepreneurial endevours at many different stages of company development, he is a welcome addition to our team.
January 2009
William Huisman joins Sirigen’s chemistry team.
William Huisman joined Sirigen in January 2009. He received his Biochemistry degree from the university of California in Los Angeles. He did his post doctoral studies at the Veterans Administration Hospital in San Diego and at San Diego State University; and has worked for International Immunology.
He brings extensive chromatography experience including analytical HPLC and preparative FPLC including ion exchange, size exclusion and affinity purifications. He has also been an internal auditor in an ISO 9000 environment.
October 2008
Sirigen headquarters
Sirigen has relocated its headquarters to Ringwood, Hampshire on the south coast of England. The modern facility houses the Group’s CEO, CFO, commercial team, finance, IT, HR and administration.
September 2008
Lan Tran and Jennifer Alcantar join Sirigen’s chemistry team to accelerate the production of new polymers.
Lan, a Pharmacological Chemistry graduate of the University of California, San Diego specialises in the multi-step synthesis of organic compounds and their analysis.
Jennifer gained her Chemistry degree from the University of California, Santa Barbara and has worked for MicroConstants, Nanosyn and BioFocus. She now also brings her valuable synthetic, analytical, purifications and QA experience to Sirigen.
15 September 2008
Sirigen launches Project Green for Luminex Partners
Sirigen is pleased to announce a commercial programme to accelerate implementation of High Sensitivity Fluorescence on the Luminex family of instruments. Development of a 532nm polymer for the reporter channel of these instruments will deliver improved analytical sensitivity in both immuno and molecular applications. Interested parties are encouraged to contact Sirigen to find out how they can be amongst the first to benefit from this initiative.
10 August 2008
San Diego move
Sirigen moves its chemistry and applications biology team to new premises in San Diego. The well equipped laboratories offer the substantially enlarged team the space and extra facilities they require. Sirigen further benefits from an excellent pool of candidates from which to make further appointments and increased participation in the world class local biotech community.
April 2008
Seraphim Capital
Seraphim Capital, the £30 million Enterprise Capital Fund led a £2 million round of Series B investment in Sirigen alongside Oxford Capital Partners. The investment enables Sirigen to continue to exploit its technology across the £47 billion biomedical industry.